Immatics N.V., a clinical-stage biopharmaceutical company, has announced that Bristol Myers Squibb (BMS) will be investing $35 million in the company. BMS acquired 2,419,818 ordinary shares of Immatics through a private placement transaction at a price of $14.461 per share. As part of the investment, BMS also gained the right to appoint a member to the Immatics Scientific Advisory Board.
Harpreet Singh, CEO and Co-Founder of Immatics, expressed confidence in their strong relationship with BMS and their platform technologies that support TCR-based cell therapies and bispecifics. Singh emphasized their commitment to advancing innovative cancer treatment options for patients and expects to release further clinical results later this year.
It is important to note that the securities involved in this investment have not been registered under applicable securities laws and may not be offered or sold in the United States without proper registration or exemption.
Immatics is dedicated to combining true targets for cancer immunotherapies with specific T-cell receptors (TCRs).